Google
LYRA Stock Price & Analysis — Lyra Therapeutics Inc (Healthcare >> Biotechnology)
LYRA FAQ
What is LYRA's ROE?
Lyra Therapeutics Inc reports a Return on Equity (ROE) of 269.84%.
What is LYRA's dividend yield?
Lyra Therapeutics Inc offers a dividend yield of 0.00%.
What is LYRA's Quality Score?
Our AI rates LYRA's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LYRA?
Our AI Timing Score for LYRA is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LYRA belong to?
Lyra Therapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
LYRA AI Analysis Summary
Our AI summary for LYRA: Lyra Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 269.84%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.40
Price
-0.08
(-15.79%)
Day Change
|
|
|---|
LYRA, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 75 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.40 |
| PBV / Sector |
-0.58 / 44,105.10
|
| Earning Per Share | -1.86 |
| PE / Sector |
N/A / 19.37
|
| PEG or PE/Growth / Sector |
N/A / 1.06
|
| Average 1M Daily Value |
6677.402815000000
|
| Average 1W Daily Value |
353.020000000000
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
58% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-06 08:00:18 |
| Symbol | LYRA |
| Name | LYRA THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 1.77 M |
| Par Value | N/A |
| Calculated From | YearEnd |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 6.21 / 9,702.21 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 480 Arsenal Way, Watertown, MA, United States, 02472
Phone: 617 393 4600
Website: https://lyratherapeutics.com
Sector: Healthcare >> Biotechnology
Description: Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap